Breast cancer

29 September 2010

Scientists Detect Unique Marker for Triple-Negative Breast Cancer

It may one day offer a more targeted therapy for the aggressive disease, but more study is needed, researchers say

This article has not necessarily been edited by Health24.

TUESDAY, Sept. 28 (HealthDay News) -- In an effort to improve the prognosis of patients battling triple-negative breast cancer, scientists have identified a unique biomarker that may eventually allow some to receive a more targeted treatment.

Although relatively uncommon, triple negative breast cancer is notoriously difficult to treat because receptor targeted therapies don't work. The disease's name refers to breast cancers that test negative for estrogen receptors, progesterone receptors, and human epidermal growth factor receptor 2(HER2), all of which fuel most breast cancer growth.

"Triple-negative breast cancers currently lack therapeutic targets and are managed with conventional chemotherapy," study author Dr. Agnieszka K. Witkiewicz, an associate professor of pathology at Thomas Jefferson University Hospital in Philadelphia, explained in a news release.

In search of new treatment targets, the study's research team analyzed expression levels of a particular protein called IGF-1R (insulin-like growth factor) among 97 patients diagnosed with triple-negative breast cancer. Seventy-three of the patients were white, and 24 were black.

Witkiewicz and her colleagues found that when it came to IGF-1R, more is better. High expression of the protein was tied to a lower risk for lymph node metastasis (spread of the cancer) and had a borderline association with smaller tumor size. High expression levels were also linked to longer survival rates among patients younger than 55.

Among the study patients, about one in four demonstrated IGF-1R over-expression.

Noting that IGF-IR has already proven to be a successful target in sarcoma treatment, Witkiewicz said it might ultimately prove to be a good target for triple-negative breast cancer as well.

"For now, we know that it is there and we know it is a marker of better prognosis," said Witkiewicz. "The next step is to learn if triple-negative breast cancer patients benefit from targeting IGF-1R."

Witkiewicz and her colleagues are slated to present their findings Tuesday at the American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development in Denver.

More information

For more on triple-negative breast cancer, visit the Triple Negative Breast Cancer Foundation.

(Copyright © 2010 HealthDay. All rights reserved.)


Read Health24’s Comments Policy

Comment on this story
Comments have been closed for this article.

Ask the Expert

Breast cancer expert

Dr Gudgeon qualified in Birmingham, England, in 1968. She has more than 40 years experience in oncology, and in 1994 she founded her practice, Cape Breast Care, where she treats benign and malignant breast cancers. Dr Boeddinghaus obtained her qualification at UCT Medical School in 1994 and her MRCP in London in 1998. She has worked extensively in the field of oncology and has a special interest in the hormonal management of breast cancer. She now works with Dr Gudgeon at Cape Breast Care. Read more.

Still have a question?

Get free advice from our panel of experts

The information provided does not constitute a diagnosis of your condition. You should consult a medical practitioner or other appropriate health care professional for a physical exmanication, diagnosis and formal advice. Health24 and the expert accept no responsibility or liability for any damage or personal harm you may suffer resulting from making use of this content.

* You must accept our condition

Forum Rules